Louisiana lawmakers have passed a bill to create a psychedelic-assisted therapy pilot program, using opioid settlement dollars to fund clinical trials aimed at developing alternative treatments such as psilocybin and ibogaine, also adopting a new amendment that adds MDMA to the scope of the legislation.
The proposal from Sen. Patrick McMath (R) was amended and approved by the House of Representatives in a 97-0 vote on Thursday, weeks after passing the Senate in a unanimous vote.
Because an amendment adopted on the House floor added MDMA to the bill, and the Health and Welfare Committee previously made technical amendments to the proposal last month, it must now go back for an additional vote in the Senate before potentially heading to the desk of Gov. Jeff Landry (R) for consideration.
Rep. Neil Riser (R), who presented the legislation to the House, said the amendment adding MDMA “put us in positive correlation” with a psychedelics executive order recently signed by President Donald Trump “so that we can look at all different alternatives, including those that are beyond ibogaine that were listed it in the executive order.”
He discussed psychedelics as a much-needed alternative treatment option for military veterans and others dealing with
Read full article on Marijuana Moment
